Pharma companies are investing in research and development to bring innovative medicines to the market suiting different age groups and their typical needs. Type 2 diabetes has been in focus for the players, being the most prevalent category for the past five years. Sales projections of oral anti-diabetic drugs indicate an edge over injected drugs in recent past. Conventional insulin and inhibitors may suffer a setback owing to advanced preventive drugs currently under clinical trials. Reports published by Big Market Research for the diabetes segment in the pharmaceutical market take a quantitative approach to the global market scenario. The study of market structure and areas promising growth and opportunities have been mapped. It revises the market activities of the global leaders of recent past noting the key drivers and restraints for the market expansion. Financial trends over the years provide a fair idea to interested scholars and investors.
No of Reports 0